Amarillo Biosciences, Inc. (AMAR.OB) Ships Clinical Supplies to Taiwan for Hepatitis C Study
Amarillo Biosciences, Inc. announced this morning that clinical supplies were shipped to CytoPharm, Inc., its partner in Taiwan, for use in a study of 165 patients with chronic hepatitis C virus infection. The objective of this trial is to reduce the virologic relapse rate for those patients who have taken high dose injectable interferon alpha and Ribavirin. The trial’s start date is anticipated to occur in the second quarter of this year and to be completed next year. The patients participating in the study will receive one of two different dosages of oral human interferon alpha or placebo daily for…